Creators of Cycloset®*, the first and only FDA approved sympatholytic dopamine D2 receptor agonist for the treatment of type 2 diabetes.
*See full prescribing info

Veroscience > News > VeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
News

VeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14

June 11, 2016 By Vera
This article is sourced from an external publication. Read the original →

https://www.prnewswire.com/news-releases/veroscience-continues-to-explore-clinical-benefits-of-circadian-neuroendocrine-resetting-therapy-with-six-papers-presented-at-2016-american-diabetes-association-scientific-sessions-june-10-14-300283267.html

Website by Axxiem
© Copyright . All Right Reserved